» Articles » PMID: 20880830

Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models

Overview
Specialty Psychiatry
Date 2010 Oct 1
PMID 20880830
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical concepts of mental illness have always been modulated by underlying theoretical considerations. For the past fifty years, schizophrenia has been considered primarily a disease of dopaminergic neurotransmission. Although this conceptualization has helped greatly in explaining the clinical effects of psychostimulants and guiding the clinical use of both typical and atypical antipsychotics, it has nevertheless shaded how we look at the disorder from both a pathophysiological and therapeutic perspective. For example, most explanatory research in schizophrenia has focused on dopamine-rich regions of the brain, with little investigation of regions of the brain that are relatively dopamine poor. Starting approximately twenty years ago, an alternative formulation of schizophrenia was proposed based upon actions of the "dissociative anesthetic" class of psychotomimetic agents, including phencyclidine (PCP), ketamine and various designer drugs. These compounds induce psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors, suggesting an alternative model for pathogenesis in schizophrenia. As opposed to dopamine, the glutamatergic system is widely distributed throughout the brain and plays a prominent role in sensory processing as well as in subsequent stages of cortical analysis. Glutamatergic theories of schizophrenia, thus, predict that cortical dysfunction will be regionally diffuse but process specific. In addition, NMDA receptors incorporate binding sites for specific endogenous brain compounds, including the amino acids glycine and D-serine and the redox modulator glutathione, and interact closely with dopaminergic, cholinergic and γ-aminobutyric acid (GABA)-ergic systems. Glutamatergic theories, thus, open new potential approaches for treatment of schizophrenia, most of which are only now entering clinical evaluation.

Citing Articles

Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.

Govil P, Kantrowitz J CNS Drugs. 2025; 39(3):243-262.

PMID: 39799532 DOI: 10.1007/s40263-024-01151-7.


Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases.

Seillier C, Lesept F, Toutirais O, Potzeha F, Blanc M, Vivien D Int J Mol Sci. 2022; 23(18).

PMID: 36142247 PMC: 9499580. DOI: 10.3390/ijms231810336.


Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders.

Aryutova K, Stoyanov D Int J Mol Sci. 2021; 22(17).

PMID: 34502214 PMC: 8430741. DOI: 10.3390/ijms22179309.


The Effect of Smartphone-Based Cognitive Training on the Functional/Cognitive Markers of Schizophrenia: A One-Year Randomized Study.

Krzystanek M, Krysta K, Borkowski M, Skalacka K, Przybylo J, Palasz A J Clin Med. 2020; 9(11).

PMID: 33207811 PMC: 7696401. DOI: 10.3390/jcm9113681.


Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia .

de la Garrigue N, Glasser J, Sehatpour P, Iosifescu D, Dias E, Carlson M J Psychiatr Brain Sci. 2020; 5(4).

PMID: 32856005 PMC: 7448686.


References
1.
Ho B, Andreasen N, Nopoulos P, Fuller R, Arndt S, Cadoret R . Secondary prevention of schizophrenia: utility of standardized scholastic tests in early identification. Ann Clin Psychiatry. 2005; 17(1):11-8. DOI: 10.1080/10401230590905272. View

2.
Reichenberg A, Weiser M, Rapp M, Rabinowitz J, Caspi A, Schmeidler J . Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005; 62(12):1297-304. DOI: 10.1001/archpsyc.62.12.1297. View

3.
Keefe R, Bilder R, Harvey P, Davis S, Palmer B, Gold J . Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006; 31(9):2033-46. DOI: 10.1038/sj.npp.1301072. View

4.
Javitt D . Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry. 2006; 19(2):151-7. DOI: 10.1097/01.yco.0000214340.14131.bd. View

5.
Kegeles L, Abi-Dargham A, Zea-Ponce Y, Mann J, van Heertum R, Cooper T . Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000; 48(7):627-40. DOI: 10.1016/s0006-3223(00)00976-8. View